NCT03421678

Brief Summary

The study will investigate the role of 1,3-butadiene metabolic activation and deactivation in lung cancer risk among various ethnic/racial groups. This project will require urine samples from smokers and nonsmokers from the three ethnic/racial groups recruited by the Clinical and Biomarker Core for the analysis of 1,3-butadiene DNA adducts. Data on nicotine intake (urinary TNE) in these subjects as well as in 400 lung cancer cases and 400 controls from Project 1 will be also required for this project.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2020

Typical duration for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 5, 2018

Completed
2.7 years until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

October 5, 2020

Status Verified

September 1, 2020

Enrollment Period

2.7 years

First QC Date

January 23, 2018

Last Update Submit

September 30, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Butadiene-DNA adducts in different ethnic groups

    Investigate ethnic differences in butadiene-DNA adducts in smokers belonging to different ethnic groups.

    Day 1 & 2

  • Butadiene-DNA adduct load in smokers with lung cancer

    Investigate the association between butadiene-DNA adduct load and lung cancer development in smokers.

    Day 1 & 2

  • Polymorphisms of carnicogen metabolizing genes

    Examine how polymorphisms of carcinogen metabolizing genes influence metabolic inactivation, DNA adduct formation/repair, and toxicity of butadiene-derived epoxides.

    Day 1 & 2

Study Arms (3)

Japanese American

Two parents of Japanese descent

Diagnostic Test: Urine Sample

Non-Hispanic Whites

Two parents of non-Hispanic white descent

Diagnostic Test: Urine Sample

Native Hawaiians

At least one parent of Hawaiian descent

Diagnostic Test: Urine Sample

Interventions

Urine SampleDIAGNOSTIC_TEST

One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine

Japanese AmericanNative HawaiiansNon-Hispanic Whites

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Approximately 300 smokers will be recruited from the Multiethnic Cohort (MEC) study or the general population in Hawai'i

You may qualify if:

  • One of the three targeted ethnic groups:
  • Japanese American - two parents of Japanese descent
  • Non-Hispanic Whites - two parents of non-Hispanic white descent
  • Native Hawaiians will include individuals with at least one parent of Hawaiian descent;
  • Smoke 5 cigarettes per day over the past three months;
  • \>21 years of age;
  • Consumes 14 or fewer drinks of alcohol per week;
  • Generally stable and good health (determined by review of medical history);
  • Able to provide written voluntary consent before performance of any study related procedure.

You may not qualify if:

  • Current use of other nicotine containing products for \> 4 times per month (and no use of any nicotine-containing products except cigarettes for 2 weeks prior to their study visits);
  • Acute or uncontrolled medical or psychiatric conditions;
  • Currently taking any medications that affect relevant metabolic enzymes or anti- inflammatory medications such as ibuprofen (this will be reviewed by study investigators on a case-by-case basis);
  • Active infection (e.g., influenza, cold, respiratory infection, sinus infection) at the time of the visit;
  • Pregnant or nursing or planning on becoming pregnant during the study;
  • Unable to read and understand English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Dorothy Hatsukami, Ph.D.

    University of Minnesota, Department of Psychiatry

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2018

First Posted

February 5, 2018

Study Start

October 1, 2020

Primary Completion

June 1, 2023

Study Completion

June 1, 2023

Last Updated

October 5, 2020

Record last verified: 2020-09